What is Inebilizumab: Uses, Dosage, Side Effects and More

Inebilizumab is a specialized medication designed to treat neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune condition that attacks the optic nerves and spinal cord. This medication works by targeting specific immune cells called B cells that contribute to the inflammation and damage seen in NMOSD.

If you or someone you care about has been diagnosed with NMOSD, you're likely feeling overwhelmed by the complexity of this condition. Understanding your treatment options, including inebilizumab, can help you feel more confident about managing this challenging diagnosis.

What is Inebilizumab?

Inebilizumab is a monoclonal antibody medication that helps control neuromyelitis optica spectrum disorder by targeting your immune system. It's specifically designed to bind to CD19-positive B cells, which are immune cells that play a key role in the autoimmune attack that characterizes NMOSD.

This medication belongs to a class of drugs called immunosuppressants, meaning it reduces your immune system's activity. While this might sound concerning, it's actually helpful in NMOSD because your immune system is mistakenly attacking healthy tissue in your nervous system.

The drug is given as an intravenous infusion, which means it's delivered directly into your bloodstream through a vein. This method ensures the medication reaches the right places in your body where it can be most effective.

What is Inebilizumab Used For?

Inebilizumab is primarily used to treat adults with neuromyelitis optica spectrum disorder (NMOSD). NMOSD is a rare autoimmune condition where your immune system attacks the protective covering around your optic nerves and spinal cord, causing inflammation and damage.

This medication is specifically approved for people who test positive for aquaporin-4 (AQP4) antibodies, which are found in about 70-80% of people with NMOSD. These antibodies are like molecular markers that help doctors confirm the diagnosis and predict how the disease might progress.

The main goal of inebilizumab treatment is to prevent relapses or attacks of NMOSD. During a relapse, you might experience symptoms like vision loss, weakness, numbness, or problems with bladder and bowel function. By reducing the frequency of these attacks, inebilizumab helps preserve your neurological function and quality of life.

How Does Inebilizumab Work?

Inebilizumab works by targeting and depleting CD19-positive B cells in your immune system. B cells are white blood cells that normally help fight infections, but in NMOSD, they contribute to the autoimmune attack on your nervous system.

Think of your immune system as an overzealous security team that's mistakenly attacking your own body. Inebilizumab acts like a supervisor that specifically removes the security guards (B cells) that are causing the most trouble, while leaving other parts of your immune system intact.

This is considered a moderately strong immunosuppressive medication. It's more targeted than some older immunosuppressants, which means it can be effective while potentially causing fewer side effects than broader immune-suppressing drugs.

The medication stays in your system for several months after each infusion, providing ongoing protection against NMOSD relapses. Most people need infusions every six months to maintain this protective effect.

How Should I Take Inebilizumab?

Inebilizumab is given as an intravenous infusion at a medical facility, typically a hospital or infusion center. You cannot take this medication at home, as it requires careful monitoring by healthcare professionals during administration.

Before each infusion, you'll usually receive pre-medications to help prevent infusion reactions. These might include antihistamines like diphenhydramine (Benadryl) and corticosteroids like methylprednisolone. Your healthcare team will give you these medications about 30-60 minutes before your inebilizumab infusion.

The infusion itself takes about 90 minutes for the first dose and about 60 minutes for subsequent doses. You'll be seated comfortably during this time, and nurses will monitor your vital signs and watch for any signs of reaction.

You don't need to follow any special dietary restrictions before or after your infusion. However, it's a good idea to eat a light meal before coming to your appointment and stay well-hydrated. Some people find it helpful to bring a book, tablet, or other quiet activities to pass the time during the infusion.

How Long Should I Take Inebilizumab For?

Inebilizumab is typically a long-term treatment for NMOSD, and many people continue taking it indefinitely to prevent relapses. The duration of treatment depends on how well you respond to the medication and whether you experience any significant side effects.

Most people start with two initial infusions given two weeks apart, followed by maintenance infusions every six months. Your doctor will monitor your condition closely during the first year to assess how well the medication is working for you.

Some people may be able to space out their infusions further apart if they remain stable and relapse-free for an extended period. However, stopping the medication completely often leads to a return of disease activity, so most people need to continue treatment long-term.

Your healthcare team will regularly evaluate your response to treatment and any side effects you might be experiencing. They'll help you weigh the benefits of continuing treatment against any risks or challenges you might face.

What Are the Side Effects of Inebilizumab?

Like all medications, inebilizumab can cause side effects, though many people tolerate it well. Understanding what to expect can help you recognize normal reactions versus concerning symptoms that need immediate attention.

The most common side effects you might experience include:

• Urinary tract infections (UTIs)
• Joint pain or arthralgia
• Infusion reactions like fever, chills, or rash
• Back pain
• Fatigue
• Headache
• Dizziness

Infusion reactions are perhaps the most immediate concern during treatment. These typically occur during or shortly after the infusion and can include symptoms like fever, chills, nausea, headache, or skin rash. Your healthcare team is well-prepared to manage these reactions if they occur.

More serious but less common side effects can include severe infections, since inebilizumab suppresses your immune system. You might be more susceptible to bacterial, viral, or fungal infections, particularly in the respiratory tract or urinary system.

Very rarely, some people may experience reactivation of dormant viruses like hepatitis B or develop a serious brain infection called progressive multifocal leukoencephalopathy (PML). Your doctor will screen for these risks before starting treatment and monitor you carefully throughout your treatment course.

Who Should Not Take Inebilizumab?

Inebilizumab isn't appropriate for everyone with NMOSD. Your doctor will carefully evaluate your medical history and current health status before recommending this treatment.

You should not take inebilizumab if you have an active, serious infection that hasn't been treated and resolved. This includes bacterial infections like pneumonia, viral infections like hepatitis B, or fungal infections that could worsen with immune suppression.

People with a history of hepatitis B infection require special consideration, as inebilizumab can cause the virus to reactivate. Your doctor will test for hepatitis B before starting treatment and may recommend antiviral medications if needed.

If you're pregnant or planning to become pregnant, inebilizumab is not recommended. The medication can cross the placenta and potentially affect your developing baby's immune system. Women of childbearing age should use effective contraception during treatment and for six months after the last dose.

People with certain types of cancer, particularly blood cancers, may not be good candidates for inebilizumab. Your doctor will evaluate your cancer history and current status when considering this treatment option.

Inebilizumab Brand Name

Inebilizumab is marketed under the brand name Uplizna in the United States. This is the commercial name you'll see on your prescription and medication packaging.

The full generic name is inebilizumab-cdon, where "cdon" refers to the specific manufacturing process used to create this monoclonal antibody. You might see this full name on some medical documents or insurance paperwork.

Uplizna is manufactured by Horizon Therapeutics and was approved by the FDA in 2020 for the treatment of NMOSD in adults. It's currently the only brand name version of inebilizumab available in the United States.

Inebilizumab Alternatives

If inebilizumab isn't the right choice for you, there are other treatment options available for NMOSD. The choice depends on your specific situation, other health conditions, and how you've responded to previous treatments.

Rituximab is another B-cell depleting medication that's commonly used for NMOSD, though it's used "off-label" for this condition. It works similarly to inebilizumab by targeting B cells but has a longer track record of use in various autoimmune conditions.

Eculizumab (Soliris) is another FDA-approved medication for NMOSD that works differently than inebilizumab. Instead of targeting B cells, it blocks part of the complement system, which is another component of the immune system involved in NMOSD.

Satralizumab (Enspryng) is a newer option that targets interleukin-6, a protein that promotes inflammation. It can be given as a subcutaneous injection, which some people prefer over intravenous infusions.

Traditional immunosuppressive medications like azathioprine, mycophenolate mofetil, or corticosteroids may also be used, particularly if the newer medications aren't accessible or appropriate for your situation.

Is Inebilizumab Better Than Rituximab?

Both inebilizumab and rituximab are effective treatments for NMOSD, but they have some important differences that might make one more suitable for your particular situation.

Inebilizumab has the advantage of being specifically approved by the FDA for NMOSD, which means it has undergone rigorous clinical trials specifically for this condition. The clinical trial data showed that inebilizumab reduced the risk of NMOSD relapses by about 73% compared to placebo.

Rituximab, while widely used for NMOSD, is prescribed "off-label" for this condition. However, it has been used for NMOSD for many years and has a well-established safety profile. Some doctors prefer rituximab because of their extensive experience with it.

The dosing schedules differ between these medications. Inebilizumab is given every six months after the initial two doses, while rituximab might be given more frequently initially, then spaced out to every six to twelve months depending on your response.

Cost and insurance coverage can also play a role in the decision. Your healthcare team will work with you to determine which medication is most appropriate based on your medical history, preferences, and practical considerations like insurance coverage.